{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T13:27:57Z","timestamp":1793798877759,"version":"4.6.1"},"reference-count":45,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T00:00:00Z","timestamp":1787097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,11,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Methotrexate (MTX) remains the anchor drug in the management of rheumatoid arthritis. However, its clinical use is frequently limited by intolerance, leading to dose reduction or discontinuation. In addition, oral MTX exhibits pharmacokinetic limitations, including dose-dependent absorption and reduced bioavailability at higher doses, which may compromise therapeutic efficacy. Subcutaneous (SC) MTX has emerged as a strategy to overcome these limitations by providing more consistent bioavailability and potentially improved tolerability. Evidence suggests that switching from oral-to-SC MTX may improve gastrointestinal intolerance and support treatment persistence, whereas evidence for improved disease control or reduction of serious MTX-related toxicity remains limited. Recent Japanese studies suggest the potential utility of this approach at MTX doses commonly used in Japan, although evidence for the superiority of SC MTX over oral MTX in low-dose settings remains limited. This narrative review summarizes current evidence on MTX intolerance and oral-to-SC route switching in rheumatoid arthritis, with a focus on practical strategies for treatment optimization. Overall, oral-to-SC MTX switching may represent an important option to improve gastrointestinal intolerance and support treatment persistence in patients with rheumatoid arthritis.<\/jats:p>","DOI":"10.1093\/mr\/roag070","type":"journal-article","created":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T11:39:09Z","timestamp":1787053149000},"page":"869-875","source":"Crossref","is-referenced-by-count":0,"title":["Managing methotrexate intolerance in rheumatoid arthritis: The role of oral-to-subcutaneous switching"],"prefix":"10.1093","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8651-4149","authenticated-orcid":false,"given":"Shin-ichiro","family":"Ohmura","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Seirei Hamamatsu General Hospital , Hamamatsu, Shizuoka ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,19]]},"reference":[{"key":"2026110407434417100_ref1","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1136\/annrheumdis-2019-216655","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update","volume":"79","author":"Smolen","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"2026110407434417100_ref2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/mr\/roac017","article-title":"Drug treatment algorithm and recommendations from the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis-secondary publication","volume":"33","author":"Kawahito","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026110407434417100_ref3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/mr\/road098","article-title":"Japan College of Rheumatology guidance for the use of methotrexate in patients with rheumatoid arthritis: secondary publication","volume":"34","author":"Kameda","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2026110407434417100_ref4","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1002\/art.21655","article-title":"Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial","volume":"54","author":"Heijde","year":"2006","journal-title":"Arthritis Rheum"},{"key":"2026110407434417100_ref5","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/art.20982","article-title":"Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti- tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study","volume":"52","author":"Smolen","year":"2005","journal-title":"Arthritis Rheum"},{"key":"2026110407434417100_ref6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/annrheumdis-2015-207511","article-title":"The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-naive early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression","volume":"75","author":"Atsumi","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026110407434417100_ref7","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/mr\/roae006","article-title":"Trends in treatment for patients with late-onset rheumatoid arthritis in Japan: data from the NinJa study","volume":"34","author":"Matsui","year":"2024","journal-title":"Mod Rheumatol"},{"key":"2026110407434417100_ref8","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.1093\/rheumatology\/keaf246","article-title":"Transition of clinical remission rates with molecular targeted therapies in rheumatoid arthritis in Japan: insights from the FIRST registry","volume":"64","author":"Kubo","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026110407434417100_ref9","doi-asserted-by":"crossref","first-page":"rkae019","DOI":"10.1093\/rap\/rkae019","article-title":"Effectiveness and safety of treat-to-target strategy for methotrexate-na\u00efve rheumatoid arthritis patients &gt;75\u2009years of age","volume":"8","author":"Matsumoto","year":"2024","journal-title":"Rheumatol Adv Pract"},{"key":"2026110407434417100_ref10","doi-asserted-by":"crossref","first-page":"e15029","DOI":"10.1111\/1756-185X.15029","article-title":"Assessment of oral methotrexate intolerance in Japanese adult patients with rheumatoid arthritis","volume":"27","author":"Kanda","year":"2024","journal-title":"Int J Rheum Dis"},{"key":"2026110407434417100_ref11","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s41927-025-00466-2","article-title":"High prevalence of methotrexate intolerance in rheumatoid arthritis patients: a cross-sectional study","volume":"9","author":"Nalwa","year":"2025","journal-title":"BMC Rheumatol"},{"key":"2026110407434417100_ref12","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1136\/annrheumdis-2014-205228","article-title":"Head-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses \u226515\u00a0mg may be overcome with subcutaneous administration","volume":"73","author":"Schiff","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2026110407434417100_ref13","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1136\/annrheumdis-2014-206504","article-title":"The comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritis","volume":"75","author":"Hazlewood","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"2026110407434417100_ref14","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.3899\/jrheum.110481","article-title":"Effects of changing from oral to subcutaneous methotrexate on red blood cell methotrexate polyglutamate concentrations and disease activity in patients with rheumatoid arthritis","volume":"38","author":"Stamp","year":"2011","journal-title":"J Rheumatol"},{"key":"2026110407434417100_ref15","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1093\/mr\/roac103","article-title":"Efficacy and tolerability of subcutaneously administered methotrexate including dose escalation in long-term treatment of rheumatoid arthritis in a Japanese population","volume":"33","author":"Tanaka","year":"2023","journal-title":"Mod Rheumatol"},{"key":"2026110407434417100_ref16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/art.23144","article-title":"Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial","volume":"58","author":"Braun","year":"2008","journal-title":"Arthritis Rheum"},{"key":"2026110407434417100_ref17","doi-asserted-by":"crossref","first-page":"591","DOI":"10.4103\/0253-7613.190761","article-title":"Hepatic and hematological adverse effects of long-term low-dose methotrexate therapy in rheumatoid arthritis: an observational study","volume":"48","author":"Dubey","year":"2016","journal-title":"Indian J Pharmacol"},{"key":"2026110407434417100_ref18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.3899\/jrheum.130270","article-title":"A clinical, pathological, and genetic characterization of methotrexate-associated lymphoproliferative disorders","volume":"41","author":"Yamakawa","year":"2014","journal-title":"J Rheumatol"},{"key":"2026110407434417100_ref19","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1016\/S0889-857X(05)70368-9","article-title":"Does methotrexate increase the risk of infection or malignancy?","volume":"23","author":"Kanik","year":"1997","journal-title":"Rheum Dis Clin N Am"},{"key":"2026110407434417100_ref20","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/S0049-0172(95)80009-3","article-title":"Infections during low-dose methotrexate treatment in rheumatoid arthritis","volume":"24","author":"Boerbooms","year":"1995","journal-title":"Semin Arthritis Rheum"},{"key":"2026110407434417100_ref21","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1136\/ard.50.1.67-b","article-title":"Cytomegalovirus pneumonia in a patient with rheumatoid arthritis treated with low dose methotrexate and prednisone","volume":"50","author":"Clerc","year":"1991","journal-title":"Ann Rheum Dis"},{"key":"2026110407434417100_ref22","first-page":"1172","article-title":"Complications of immunosuppression associated with weekly low dose methotrexate","volume":"18","author":"Shiroky","year":"1991","journal-title":"J Rheumatol"},{"key":"2026110407434417100_ref23","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1164\/ajrccm.150.1.8025760","article-title":"Opportunistic infection during treatment with low dose methotrexate","volume":"150","author":"LeMense","year":"1994","journal-title":"Am J Respir Crit Care Med"},{"key":"2026110407434417100_ref24","doi-asserted-by":"crossref","first-page":"997","DOI":"10.2169\/internalmedicine.8205-21","article-title":"Factors associated with Pneumocystis jirovecii pneumonia in patients with rheumatoid arthritis receiving methotrexate: a single-center retrospective study","volume":"61","author":"Ohmura","year":"2022","journal-title":"Intern Med"},{"key":"2026110407434417100_ref25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.62.5.423","article-title":"Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis","volume":"62","author":"Hoekstra","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"2026110407434417100_ref26","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1002\/art.1780371013","article-title":"Methotrexate in rheumatoid arthritis. A five-year prospective multicenter study","volume":"37","author":"Weinblatt","year":"1994","journal-title":"Arthritis Rheum"},{"key":"2026110407434417100_ref27","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1111\/1756-185X.14207","article-title":"Assessing methotrexate intolerance and its prevalence in rheumatoid arthritis: development and validation of the MISA questionnaire","volume":"24","author":"Vijaykumar","year":"2021","journal-title":"Int J Rheum Dis"},{"key":"2026110407434417100_ref28","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1007\/s00296-016-3621-1","article-title":"Oral to subcutaneous methotrexate dose-conversion strategy in the treatment of rheumatoid arthritis","volume":"37","author":"Schiff","year":"2017","journal-title":"Rheumatol Int"},{"key":"2026110407434417100_ref29","doi-asserted-by":"crossref","first-page":"3426","DOI":"10.1093\/rheumatology\/keaf054","article-title":"Comparison of the efficacy and safety of methotrexate injection and methotrexate tablets in active RA","volume":"64","author":"Qiao","year":"2025","journal-title":"Rheumatology (Oxford)"},{"key":"2026110407434417100_ref30","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/acr.24334","article-title":"Safety and tolerability of subcutaneous methotrexate in routine clinical practice","volume":"73","author":"Li","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2026110407434417100_ref31","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1007\/s10067-010-1500-9","article-title":"When should we use parenteral methotrexate?","volume":"29","author":"Mainman","year":"2010","journal-title":"Clin Rheumatol"},{"key":"2026110407434417100_ref32","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"2026110407434417100_ref33","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1093\/rheumatology\/keab313","article-title":"Effectiveness and tolerability of oral vs subcutaneous methotrexate in patients with rheumatoid arthritis","volume":"61","author":"Heuvelmans","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"2026110407434417100_ref34","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1136\/ard.2009.124065","article-title":"Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study","volume":"69","author":"Bakker","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2026110407434417100_ref35","doi-asserted-by":"crossref","first-page":"e83","DOI":"10.1111\/j.1756-185X.2010.01482.x","article-title":"Subcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritis","volume":"13","author":"Hameed","year":"2010","journal-title":"Int J Rheum Dis"},{"key":"2026110407434417100_ref36","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1093\/mr\/roaf093","article-title":"The effectiveness and safety of subcutaneous methotrexate injection in Japanese patients with rheumatoid arthritis in a real-world setting","volume":"36","author":"Shimomura","year":"2026","journal-title":"Mod Rheumatol"},{"key":"2026110407434417100_ref37","doi-asserted-by":"crossref","first-page":"18","DOI":"10.2174\/1874312901408010018","article-title":"LETTER TO THE EDITOR subcutaneous (SC) methotrexate (MTX) is better and well-tolerable than Oral MTX in rheumatoid arthritis patients, switched from oral to SC administration due to gastrointestinal side effects","volume":"8","author":"Borman","year":"2014","journal-title":"Open Rheumatol J"},{"key":"2026110407434417100_ref38","doi-asserted-by":"crossref","first-page":"751","DOI":"10.2147\/PPA.S301010","article-title":"Benefits of switch from oral to subcutaneous route on adherence to methotrexate in patients with rheumatoid arthritis in real life setting","volume":"15","author":"Senbel","year":"2021","journal-title":"Patient Prefer Adherence"},{"key":"2026110407434417100_ref39","doi-asserted-by":"crossref","first-page":"115","DOI":"10.31138\/mjr.140423.sat","article-title":"Should all patients trial subcutaneous methotrexate prior to commencing biologic therapy? A real world study","volume":"35","author":"Mirza","year":"2023","journal-title":"Mediterr J Rheumatol"},{"key":"2026110407434417100_ref40","doi-asserted-by":"crossref","first-page":"188","DOI":"10.3109\/09546634.2014.927817","article-title":"Does switching from oral to subcutaneous administration of methotrexate influence on patient reported gastro-intestinal adverse effects?","volume":"26","author":"Kromann","year":"2015","journal-title":"J Dermatolog Treat"},{"key":"2026110407434417100_ref41","first-page":"207","article-title":"Oral vs. subcutaneous low-dose methotrexate treatment in reducing gastrointestinal side effects","volume":"47","author":"Rutkowska-Sak","year":"2009","journal-title":"Reumatologia"},{"key":"2026110407434417100_ref42","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3109\/03009742.2014.910312","article-title":"Retrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR study","volume":"43","author":"Scott","year":"2014","journal-title":"Scand J Rheumatol"},{"key":"2026110407434417100_ref43","doi-asserted-by":"crossref","DOI":"10.2169\/internalmedicine.7236-26","article-title":"Efficacy of switching from oral to subcutaneous methotrexate in alleviating methotrexate-related intolerance symptoms in Japanese patients with rheumatoid arthritis: the METOJECTIVE Study","author":"Ohmura","year":"2026","journal-title":"Intern Med"},{"key":"2026110407434417100_ref44","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.semarthrit.2015.02.009","article-title":"Effectiveness, tolerability, and safety of subcutaneous methotrexate in early rheumatoid arthritis: a retrospective analysis of real-world data from the St Gallen cohort","volume":"45","author":"M\u00fcller","year":"2015","journal-title":"Semin Arthritis Rheum"},{"key":"2026110407434417100_ref45","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1007\/s10067-013-2318-z","article-title":"Cost-minimisation analysis of subcutaneous methotrexate versus biologic therapy for the treatment of patients with rheumatoid arthritis who have had an insufficient response or intolerance to oral methotrexate","volume":"32","author":"Fitzpatrick","year":"2013","journal-title":"Clin Rheumatol"}],"container-title":["Modern Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mr\/advance-article-pdf\/doi\/10.1093\/mr\/roag070\/70709113\/roag070.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/6\/869\/70709113\/roag070.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mr\/article-pdf\/36\/6\/869\/70709113\/roag070.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T12:43:51Z","timestamp":1793796231000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mr\/article\/36\/6\/869\/8766060"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,19]]},"references-count":45,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,8,19]]},"published-print":{"date-parts":[[2026,11,4]]}},"URL":"https:\/\/doi.org\/10.1093\/mr\/roag070","relation":{},"ISSN":["1439-7595","1439-7609"],"issn-type":[{"value":"1439-7595","type":"print"},{"value":"1439-7609","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,11]]},"published":{"date-parts":[[2026,8,19]]}}}